Innovus Pharmaceuticals Supplement Androferti Improves Male Fertility, says top medical expert

SAN DIEGO, CA--(Marketwired - Oct 20, 2016) - The Virginia Center for Reproductive Medicine ("VCRM"), one of the nation's leading fertility centers, today recommends Androferti®, a supplement from San Diego-based Innovus Pharmaceuticals, Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company.

The supplement can be used to help solve the growing issue of male infertility, says Fady I. Sharara, M.D., FACOG, founder and Medical Director of the (VCRM).

When couples have trouble conceiving, the conventional wisdom is that the problem lies with the woman. "But that's true in only about 40% of cases," explains Dr. Sharara. "In another 40% of cases, the problem is male fertility -- low sperm counts and poor quality sperm."

There are also disturbing data suggesting that sperm counts and quality are declining in the U.S. and around the world, because of diet, pollution, sedentary lifestyles, and other aspects of modern life. "When people do not eat well, or when they are overweight or smoke or take drugs, the sperm suffers," explains Dr. Sharara.

The good news, however, is that male fertility is a treatable problem. The steps to take, Dr. Sharara says, include taking Androferti. Here are his full recommendations:

• Stop smoking
• Cut back on drinking (and ideally, stopping entirely)
• Don't put laptop computers on laps, since that raises the temperature of the testes and damages sperm
• When exercising, don't wear tight compression shorts
• Take Androferti, which is designed to improve sperm count and quality
  
  

"We have tried a number of supplements that claim to improve sperm," explains Dr. Sharara. "Most include an amino acid called L-carnitine that has been shown to increase sperm count and movement."

But the supplements don't all work equally well. The best by far, in VCRM's experience, is Androferti®, which contains a patented formulation containing vitamin C, coenzyme Q10, and vitamin B12, in addition to L-carnitine. "We switched to Androferti® about six months ago, and the improvement we are seeing has been impressive," says Dr. Sharara. "We are seeing more than 50% improvements in sperm count, morphology, and motility. That's also similar to what has been shown in the Androferti® published human clinical trials."

"This is one of the best, if not the best, products on the market," says Dr. Sharara. "I believe it could help couples conceive the children that they so desperately want."

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's and women's health and respiratory diseases. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® to help with reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele® for promoting sexual health, (h) RecalMax™ for promoting brain and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for allergic rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.urivarx.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, results from the above pre-clinical and clinical trial, projected revenues, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.